Sanara MedTech (NASDAQ:SMTI) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Sanara MedTech (NASDAQ:SMTI) issued its quarterly earnings data on Monday. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.18, FiscalAI reports. Sanara MedTech had a negative return on equity of 20.73% and a negative net margin of 36.42%.The business had revenue of $27.80 million for the quarter, compared to the consensus estimate of $26.80 million.

Sanara MedTech Stock Down 2.1%

NASDAQ SMTI traded down $0.38 during mid-day trading on Monday, reaching $18.02. 34,353 shares of the company’s stock traded hands, compared to its average volume of 58,410. Sanara MedTech has a 1-year low of $16.05 and a 1-year high of $35.95. The company has a fifty day simple moving average of $18.82 and a 200-day simple moving average of $21.74. The company has a current ratio of 1.80, a quick ratio of 1.59 and a debt-to-equity ratio of 7.75. The company has a market cap of $165.15 million, a price-to-earnings ratio of -4.26 and a beta of 1.16.

Institutional Investors Weigh In On Sanara MedTech

A number of hedge funds have recently bought and sold shares of SMTI. Rhumbline Advisers lifted its holdings in Sanara MedTech by 14.9% during the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock worth $115,000 after buying an additional 483 shares during the last quarter. Hsbc Holdings PLC bought a new position in Sanara MedTech during the 2nd quarter worth approximately $382,000. Marshall Wace LLP lifted its holdings in Sanara MedTech by 144.3% during the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after buying an additional 42,237 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in Sanara MedTech by 63,100.0% during the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock worth $89,000 after buying an additional 3,155 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Sanara MedTech by 26.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,057 shares of the company’s stock worth $351,000 after buying an additional 2,315 shares during the last quarter. Institutional investors and hedge funds own 8.10% of the company’s stock.

Wall Street Analysts Forecast Growth

SMTI has been the topic of several recent analyst reports. Wall Street Zen downgraded Sanara MedTech from a “buy” rating to a “hold” rating in a research report on Sunday, April 5th. Zacks Research downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Sanara MedTech in a report on Monday, January 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Sanara MedTech in a report on Tuesday, April 21st. Finally, Lake Street Capital began coverage on Sanara MedTech in a report on Wednesday, April 15th. They issued a “buy” rating and a $32.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Sanara MedTech presently has an average rating of “Hold” and a consensus price target of $34.00.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.